The rise of Viagra and its effect on the medicinal landscape presents a intricate question for investors. While the early sales figures were impressive, the intellectual property has expired, leading to a wave of off-brand alternatives that are chipping away at earnings. Moreover, the sector is facing challenges related to aging trends and changing